Dokumentasjon
Femarelle er sannsynligvis det best dokumenterte naturmidlet mot overgangsplager og det mest effektive for å styrke benbygningen. De publiserte studiene finnes på nettstedet PubMed. Her er en liste over vitenskapelig dokumentasjon på alle produktene, samt et antall sammendrag og presentasjoner ved vitenskapelige kongresser over hele verden. Listen er ajour per 2021.
Femarelle® Rejuvenate
Efficacy
Safety
- Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011;18(3):285-288
- Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. Reproductive Toxicology 2005; 20(2):261-66
- Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. European J. of Obstetrics & Gynecology & Reproductive Biology 2006; 130(1):140-141 [IN-VITRO]
Femarelle® Recharge
Efficacy
Menopausal symptoms
- Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. J. of Clin Exper Obstet Gynecol 2004; 31(2):123-26 [CLINICAL]
- Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. J Endocrinol. Invest. 2013; 36(7):521-6 [CLINICAL]
Mood, sleep & fatigue
Post Marketing surveys- efficacy
- Sánchez-Borrego R, Mendoza N, Llaneza P. A prospective study of DT56a (Femarelle) for the treatment of menopause symptoms. Climacteric. 2015;18(6):813-6 [POST-MARKETING SURVEY- SPAIN]
- Chen FP et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. Taiwan J Obstet Gynecol. 2016 Jun; 55(3):336-40 [POST-MARKETING SURVEY- TAIWAN]
Safety
- Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011;18(3):285-288 [CLINICAL]
- Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. Reproductive Toxicology 2005; 20(2):261-66 [IN-VIVO]
- Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. European J. of Obstetrics & Gynecology & Reproductive Biology 2006; 130(1):140-141 [IN-VITRO]
Femarelle® Unstoppable
Efficacy
Energy & sleep
Vaginal Dryness
Bone
- Somjen D., Katzburg S. Lieberherr M., Hendel D., Yoles I. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In Vitro. J. of Steroid Biochemistry & Molecular Biology 2006; 98(1):90-96 [IN-VITRO]
- Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. J Endocrinol Invest. 2011;34(2):106-10 [IN-VIVO]
- Somjen D. et al. DT56a (Femarelle); contrary to estradiol-17β; is effective in human derived female osteoblasts in hyperglycemic condition. J Steroid Biochem Mol Biol. 2011; 123:25-29 [IN-VITRO]
Safety
- Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. European J. of Obstetrics & Gynecology & Reproductive Biology 2006; 130(1):140-141 [IN-VITRO]
- Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. Menopause 2011;18(3):285-288 [CLINICAL]
- Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. Reproductive Toxicology 2005; 20(2):261-66 [IN-VIVO]
Mechanism of Action for 3 products in the line
- Somjen D, Yoles I. DT56a (Tofupill/Femarelle), selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J. of Steroid Biochemistry & Molecular Biology 2003; 86(1):93-98 [IN-VIVO]
- Somjen D, Yoles I. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). J. of Steroid Biochemistry & Molecular Biology 2007;104:252-58 [IN-VIVO & IN-VITRO]
Overviews from external scientists that relate to Femarelle®
- Bedell S., Nachtigall M., Naftolin F. The pros and cons of plant estrogens for menopause; J. Steroid Biochem. Mol. Biol. 2014;139:225-236
- Sánchez-Borrego R. et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy; Climacteric. 2015 Jun;18(3):350-7
- Genazzani AR. DT56a, a non-hormonal botanical therapy, as first line treatment for menopausal symptoms. 12thEuropean Society of Gynecology Congress, Opening Symposium – Climacteric and Menopause: from symptoms to therapies, from security to efficacy; October 18, 2017
Effect of Femarelle on Vascular Tissue
- Somjen D, Yoles I.: “DT56a stimulates creatine kinase specific activity in vascular tissues of rats. J. of Endocrinological Investigation 2003;26(10):966-971 [IN-VIVO]
- Somjen D. et al. Interaction between the effects of the selective estrogen modulator Femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells. J Steroid Biochem Mol Biol. 2017 May 20 [Epub ahead of print] [IN-VITRO]